ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025
[A multimodal disease-specific cohort for melanoma research: Construction, governance, and preliminary report].
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGiven the high incidence, poor prognosis, and scarcity of high-quality multimodal research data for acral melanoma in the Chinese population, this study aims to build a representative multimodal disease-specific cohort to provide a high-quality data foundation for characterizing disease features and exploring mechanisms of prognosis.
methodsThis single-center prospective cohort was constructed by consecutively enrolling melanoma patients with pathological confirmation at Xiangya Hospital of Central South University between April 2016 and September 2024, while excluding minors and pregnant or lactating women. A standardized dataset comprising 16 internationally aligned core modules was built following global ontologies and clinical data standards. Data governance integrated a hybrid automated extract-transform-load (ETL) and artificial intelligence (AI)-assisted architecture. Pathology narratives were processed using Transformer-based natural language processing (NLP) models to extract textual and morphologic features, while raw imaging data were handled with deep learning pipelines for pixel-level modeling. Data quality was ensured through dual clinical-engineering validation, and outcomes were adjudicated using RECIST 1.1 and CTCAE v5.0 criteria.
resultsThe cohort included 1 036 melanoma patients, consisting of 514 males (49.614%) and 522 females (50.386%), with a mean age of (60.2±13.7) years. Among 898 patients with a known clinical subtype, 606 (67.483%) were acral melanoma, the dominant subtype. In 678 patients with complete Breslow thickness data, the median Breslow thickness was 3.25 mm. Of 612 patients with recorded Clark levels, 277 (45.261%) were Clark level IV, the most frequent category. Among 880 patients with available clinical TNM (cTNM) staging, 329 (37.386%) were stage II, representing the largest proportion; Driver mutation profiling showed
conclusionsThis melanoma-specific multimodal cohort captures population-specific clinical, imaging, digital pathology, and molecular features for the Chinese population. It establishes a scalable, governed real-world research resource to enable comparative-effectiveness studies, prognostic biomarker discovery, and future development of AI-assisted diagnostic and prognostic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.